Get started
Author

Vedran Pavlovic

Observed names: Pavlovic, Vedran, V Pavlovic, V. Pavlovic
Institution: AiCuris (Germany)
Observed institutions: Royal Children's Hospital, Shanghai Jiao Tong University, Fudan University, Ruijin Hospital, Nanfang Hospital, Roche (United Kingdom), First Hospital of Jilin University, AiCuris (Germany), Southern Medical University
ORCID: 0000-0002-9475-7201
Observed ORCID: 0000-0002-9475-7201
OpenAlex ID: A5074915165
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B
2024 · Jinlin Hou, Wenhong Zhang, et al. · New England Journal of Medicine · 113
Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study
2019 · Milan J Sonneveld, Willem P Brouwer, et al. · The Lancet. Gastroenterology & hepatology · 78
Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B
2018 · Florian van Bömmel, Alena van Bömmel, et al. · The Journal of Infectious Diseases · 75
PDF
Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B
2020 · Maria Pfefferkorn, Tina Schott, et al. · Journal of Hepatology · 73
Efficacy and Safety of Peginterferon Alfa‐2a (40KD) in Children With Chronic Hepatitis B: The PEG‐B‐ACTIVE Study
2018 · Stefan Wirth, Hongfei Zhang, et al. · Hepatology · 67
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection
2023 · Edward J. Gane, Won Kim, et al. · Journal of Hepatology · 47
Clinical Study of Single‐Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B
2021 · Edward Gane, Man‐Fung Yuen, et al. · Hepatology · 45
Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis
2020 · Milan J. Sonneveld, Willem P. Brouwer, et al. · Alimentary Pharmacology & Therapeutics · 41
A baseline tool for predicting response to peginterferon alfa‐2a in HB eAg‐positive patients with chronic hepatitis B
2018 · H. L. Y. Chan, D. Messinger, et al. · Alimentary Pharmacology & Therapeutics · 34
PDF
Quantitation of large, middle and small hepatitis B surface proteins in HBeAg‐positive patients treated with peginterferon alfa‐2a
2019 · Franziska Rinker, Corinna M. Bremer, et al. · Liver International · 23
PDF
Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study
2020 · Milan J Sonneveld, Bettina E Hansen, et al. · The Journal of Infectious Diseases · 20
PDF
Durability of Response in Children Treated With Pegylated Interferon alfa‐2a ± Ribavirin for Chronic Hepatitis C
2015 · Kathleen B. Schwarz, Jean P. Molleston, et al. · Journal of Pediatric Gastroenterology and Nutrition · 18
Long-Term Growth Outcomes in Children Treated for Chronic Hepatitis C
2014 · Maureen M. Jonas, Kathleen B. Schwarz, et al. · The Journal of Pediatrics · 17
Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B
2025 · Lisa M. van Velsen, Lesley A. Patmore, et al. · Clinical Gastroenterology and Hepatology · 14
Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data
2018 · Vedran Pavlovic, Lei Yang, et al. · Antiviral Therapy · 11
RO7062931 antisense oligonucleotide phase 1 study demonstrates target engagement in patients with chronic hepatitis B on established nucleos(t)ide therapy
2020 · Man-Fung Yuen, Edward Gane, et al. · Journal of Hepatology · 8
PDF
A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in Hepatitis B e antigen-negative chronic hepatitis B
2018 · Pietro Lampertico, Diethelm Messinger, et al. · Annals of Gastroenterology · 7
PDF
P0559 : Evaluation of large, middle and small hepatitis B surface (HBS) proteins in HBeAg positive patients
2015 · F. Rinker, C.M. Bremer, et al. · Journal of Hepatology · 5
Genetic variation in FCER1A predicts peginterferon alfa‐2a‐induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B
2019 · Lai Wei, Vedran Pavlovic, et al. · Journal of Viral Hepatitis · 4
PDF
A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B
2016 · P. Lampertico, D. Messinger, et al. · Journal of Hepatology · 3
Overrange dilution for improvement of hepatitis B core related antigen as a biomarker: protocol validation and examples for application
2025 · Maria Pfefferkorn, Jessica Brehm, et al. · Virology · 2
THU-245 Safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7565020, a novel monoclonal antibody that targets the hepatitis B surface antigen: results from a phase 1 single ascending dose study in healthy volunteers and participants with chronic hepatitis B
2025 · Man-Fung Yuen, Yan Huang, et al. · Journal of Hepatology · 2
A single ascending dose study of single‐stranded oligodeoxyribonucleotide RO7062931 in Chinese healthy volunteers
2023 · Tsang Tommy Cheung, Andrea On Yan Luk, et al. · Clinical and Translational Science · 2
PDF
Reply
2021 · Cynthia Wat, Edward Gane, et al. · Hepatology · 1
A Genotype-Specific Baseline Score to Predict Post-Treatment Response to Peginterferon Alfa-2a in HBeAg-Positive Patients with Hepatitis B Virus Genotype B or C Infection
2016 · H.L.-Y. Chan, D. Messinger, et al. · Journal of Hepatology · 1
Works count: 39
Citation count: 715
H-index: 14
I10-index: 15
Year
Topic
Type